Waratah Capital Advisors’s DexCom DXCM Stock Holding History

Waratah Capital Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-70,149	Closed	-$7.95M	–	149
2024 Q2	$7.95M	Buy	70,149 +17,570	+33%	+$2.22M	0.29%	73
2024 Q1	$7.29M	Sell	52,579 -54,049	-51%	-$6.79M	0.22%	79
2023 Q4	$13.2M	Buy	106,628 +44,221	+71%	+$4.52M	0.26%	53
2023 Q3	$5.82M	Sell	62,407 -25,709	-29%	-$2.9M	0.08%	84
2023 Q2	$11.3M	Sell	88,116 -12,021	-12%	-$1.45M	0.22%	54
2023 Q1	$11.6M	Buy	100,137 +75,734	+310%	+$8.48M	0.26%	65
2022 Q4	$2.76M	Buy	+24,403	New	+$2.68M	0.05%	98
2022 Q2	–	Sell	-7,376	Closed	-$943K	–	183
2022 Q1	$943K	Buy	+7,376	New	+$807K	0.01%	156
2019 Q4	–	Sell	-40,684	Closed	-$1.52M	–	158
2019 Q3	$1.52M	Buy	+40,684	New	+$1.58M	0.17%	93

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Waratah Capital Advisors's DXCM Position: Q3 2024 in Review

Waratah Capital Advisors sold out of DexCom (DXCM) in Q3 2024, closing a stake of 70,149 shares — an estimated $7.95M sold.

Waratah Capital Advisors first reported a position in DXCM in Q3 2019 and held it in 9 quarters. The position peaked at $13.2M in Q4 2023. 889 funds tracked by Wall St. Rank hold DXCM as of Q3 2024.

Waratah Capital Advisors reported no remaining DexCom position as of Q3 2024 after selling out during the quarter.
Waratah Capital Advisors sold 70,149 DexCom shares in Q3 2024, an estimated $7.95M.
Waratah Capital Advisors first reported a position in DexCom in Q3 2019 and held it in 9 quarters.
Waratah Capital Advisors's DexCom position peaked at $13.2M in Q4 2023.
889 funds tracked by Wall St. Rank held DexCom as of Q3 2024.

Based on Waratah Capital Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.